Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
InbioDerm A
- Development stage
- Preclinical
- Lead developer
- Instituto para el Desarrollo Biotecnológico y la Innovación
- Administration
- Topical
01
Overview
InbioDerm A (also referred to as InbioDerm+A) is a combined medical device and biomaterial developed by the Chilean biotechnology consortium Instituto para el Desarrollo Biotecnológico y la Innovación (Inbiocriotec). It consists of a ternary polymeric matrix scaffold composed of gelatin, chitosan, and hyaluronic acid, which is combined with patient-derived autologous plasma. Designed for advanced wound healing and graft bed preparation, InbioDerm A provides a supportive extracellular matrix-like microenvironment that promotes cell adhesion, proliferation, and tissue regeneration. It is compatible with negative-pressure wound therapy (NPWT) and is used to treat complex, slow-healing wounds and skin lesions.
- Brand names
- InbioDerm AInbioDerm+A
- Other names
- Inbioderm AInbioderm+A
Beyond the preview
Go deeper on InbioDerm A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InbioDerm A.